Aurora kinase

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Retrieved on: 
Saturday, October 14, 2023
Biotechnology, Practice Management, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Aurora, HIV disease progression rates, Alisertib, Biomarker, Division, Rb, Plasma, Pembrolizumab, AACR, CD56, MD Anderson Cancer Center, HNSCC, Apoptosis, DNA, Cancer, Mitosis, Membrane protein, Aurora kinase A, AURKA, University, Patient, Preclinical development, Therapy, Doctor of Philosophy, CD8, Puma Biotechnology, Retinoblastoma protein, Immunotherapy, Phase, Immunogenic cell death, Carcinoma, Thyroid, HPV, PFS, Infection, Head, Adenosine, Puma, CPS, Cytokine, Nature, Progression-free survival, Conference, Poster, Pharmaceutical industry, Vaccine, Aurora kinase

Alisertib is an adenosine triphosphate–competitive, reversible inhibitor of Aurora Kinase A (AURKA) that results in disruption of mitosis.

Key Points: 
  • Alisertib is an adenosine triphosphate–competitive, reversible inhibitor of Aurora Kinase A (AURKA) that results in disruption of mitosis.
  • A synthetic lethal relationship between AURKA and Rb1 has been implicated preclinically, and alisertib has been shown to induce immunogenic cell death in HPV+ cancer cells.
  • Based on these findings, the 40 mg dose level was selected for the Phase II portion of the study.
  • The prospect of biomarker-defined populations who may benefit most from alisertib treatment continues to be an area of great interest.”

VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Health, Oncology, Clinical Trials, Emory University, KRAS, Yale School of Medicine, PI, University, Aurora kinase A, NYU, Yale Cancer Center, NSCLC, Lung cancer, Doctor of Philosophy, ASCO, American Society of Clinical Oncology, Patient, Annual general meeting, Aurora kinase, AURKA, MPH, Therapy, DVM, Society, Pharmaceutical industry, MD

VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib.

Key Points: 
  • VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib.
  • The study targets the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC).
  • The findings were presented at the prestigious 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 4.
  • Lee, PhD, and B. Burtness, MD, Yale School of Medicine and Yale Cancer Center, T. Myers, MD, and L. Paradiso, DVM, Vitrac Therapeutics.

Ellipses Pharma Presents Preliminary Data From the First in Human Phase-1/2 Trial of EP0042, a Dual FLT-3 and Aurora Kinase Inhibitor, at ASH

Retrieved on: 
Monday, December 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Aurora, Dizziness, FLT3, Survival, International Journal of Molecular Sciences, Institute of Cancer Research, Monocyte, Canadian International Council, Diagnosis, Leukemia, Acute leukemia, Acute myeloid leukemia, Society, Patient, Cancer, Cerebral edema, Royal Marsden Hospital, Aurora kinase, Treatment, Survival rate, Ellipses, Febrile neutropenia, American Cancer Society, Drug resistance, Drug development, NHS foundation trust, Bone marrow, AML, Clinical trial, Safety, Ataxia, FIH, Cancer research, Granulocyte, Pulmonary toxicity, ASH, The Royal Marsden NHS Foundation Trust, Risk, Pharmaceutical industry, Dietary supplement, Hematology

EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.

Key Points: 
  • EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.
  • The preliminary data is based upon 25 patients across 6 dose cohorts including patients with FLT3 mutated and wild type AML at the point of enrolment.
  • The median number of prior treatments was 2 (range 1-6), with a number of patients having received a prior FLT3 inhibitor.
  • EP0042 is a dual FLT3 and Aurora kinase inhibitor under development as a potential treatment for AML patients who have developed FLT3 inhibitor resistance.

Ellipses Pharma to Present Clinical Updates at Leading U.S. Breast and Blood Cancer Conferences

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SARM, Acute leukemia, Breast cancer, AML, FLT3, ASH, Safety, Society, Aurora kinase, Exposition, Patient, Pharmaceutical industry, Birth control

At SABCS, a Trial in Progress poster that details the design of a Phase 1 / 2 trial of vosilasarm (EP0062) will be presented.

Key Points: 
  • At SABCS, a Trial in Progress poster that details the design of a Phase 1 / 2 trial of vosilasarm (EP0062) will be presented.
  • EP0062 is a selective androgen receptor modulator currently under development for the treatment of AR+/HER-/ER+ advanced breast cancer.
  • Ellipses is committed to developing novel cancer treatments at pace and getting them to patients.
  • A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer

Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Adult, Texas Oncology, Paclitaxel, Journal, List of American Medical Association journals, Adenosine, UPMC, Research, Baylor University Medical Center, Woman, Patient, Liu v. Securities and Exchange Commission, Translational research, Acute myeloid leukemia, NASDAQ, Takeda, Tablet, Food, EDT, Lymphoma, Division, Puma Biotechnology, European Commission, Aurora kinase, Annual report, Founder, Head, Doctor of Philosophy, Associate, Squamous cell carcinoma, Triple-negative breast cancer, Apoptosis, Investor, Puma, MD, FDA, Capecitabine, Neoplasm, Ovarian cancer, Breast cancer, Biotechnology, Thorax, Security (finance), Conference, UPMC Hillman Cancer Center, Aurora, Mitosis, Fulvestrant, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Royal commission, Cancer, Pharmaceutical industry, Medical imaging, Alisertib

Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of alisertib.

Key Points: 
  • Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of alisertib.
  • Puma will host a conference call today at 2:00 p.m. PDT/5:00 p.m. EDT to discuss the alisertib licensing agreement.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
ORIC, Cell death, Aurora kinase, Annual general meeting, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Twitter, PLK4, Annual report, HER2, CNS, Brain, GLOBE, Drug Quality and Security Act, Patient, Multiple myeloma, SAN, LinkedIn, Securities Exchange Act of 1934, EGFR, NSCLC, Breast, PRC2, Nasdaq, Breast cancer, SEC, Neoplasm, CD73, Prostate cancer, EED, Adenosine, Industry, Securities Act of 1933, Risk, AACR, Therapy, TRIM37, Pharmaceutical industry, Cryptocurrency, Vaccine, Cancer, MD

Our four presentations at AACR reflect the broad and diverse pipeline of differentiated programs at ORIC, said Jacob M. Chacko, MD, chief executive officer.

Key Points: 
  • Our four presentations at AACR reflect the broad and diverse pipeline of differentiated programs at ORIC, said Jacob M. Chacko, MD, chief executive officer.
  • We also introduced our highly selective inhibitors of PLK4 as a potential treatment for breast cancer by leveraging a synthetic lethal liability.
  • We look forward to the continued advancement of these programs as well as ORIC-944, with initial data for our three clinical programs expected in the first half of 2023.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Online, Nasdaq, Industry, Drug Quality and Security Act, TRIM37, AACR, Multiple myeloma, SAN, Twitter, Cell death, ORIC, Securities Act of 1933, Risk, PRC2, U.S. Securities and Exchange Commission, Therapy, Prostate cancer, CNS, Abstract (summary), Securities Exchange Act of 1934, Brain, EED, GLOBE, EGFR, Patient, CD73, Breast cancer, Security (finance), American Association, COVID-19, SEC, Association, Program, Poster, Aurora kinase, HER2, NSCLC, LinkedIn, Pharmaceutical industry, Cancer, PLK4

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations and one oral presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022, in New Orleans, LA. The presentations will highlight preclinical data regarding two Phase 1 programs, including ORIC-533, a highly potent, orally bioavailable CD73 inhibitor, and ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. The presentations will also introduce a new program targeting a synthetic lethality pathway in breast cancer.

Key Points: 
  • The presentations will also introduce a new program targeting a synthetic lethality pathway in breast cancer.
  • Taken together, these results demonstrate that the ORIC small molecule CD73 inhibitor potently inhibits the adenosine pathway,which restores anti-tumor immunity and therefore holds potential for patients with multiple myeloma.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.

Aurora Kinase Inhibitor Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Pharmaceutical, Protein kinase inhibitors, Aurora kinase, Pipeline, Aurora inhibitor

The "Aurora Kinase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aurora Kinase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Aurora Kinase Inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Aurora Kinase Inhibitor pipeline landscape.
  • This segment of the report provides insights about the different Aurora Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Aurora Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Aurora Kinase A, Pipeline Review, H2 2019 - AbbVie Inc, Cielo Therapeutics Inc & Taiho Pharmaceutical Co Ltd. - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Health, Pharmaceutical, Enzymes, Cell Cycle, Aurora A kinase, Cancer research, Protein kinase, Aurora kinase, SNRK, Casein kinases

The "Aurora Kinase A - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aurora Kinase A - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2019'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules.
  • Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression.
  • The report 'Aurora Kinase A - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.